{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:20:01Z","timestamp":1772853601482,"version":"3.50.1"},"reference-count":123,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also used in obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts mainly by antagonizing the adrenergic \u03b12, and the serotonergic 5-HT2 and 5-HT3 receptors. Neuropsychiatric symptoms, such as depression and agitation, are strongly associated with Alzheimer\u2019s disease, reducing the life quality of these patients. Thus, it is crucial to control depression in Alzheimer\u2019s patients. For this purpose, drugs such as mirtazapine are important in the control of anxiety, agitation, and other depressive symptoms in these patients. Indeed, despite some contradictory studies, evidence supports the role of mirtazapine in this regard. In this review, we will focus on depression in Alzheimer\u2019s disease, highlighting the role of mirtazapine in this context.<\/jats:p>","DOI":"10.3390\/ph14090930","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:13:47Z","timestamp":1631924027000},"page":"930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Antidepressants in Alzheimer\u2019s Disease: A Focus on the Role of Mirtazapine"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-1560","authenticated-orcid":false,"given":"Ana Salom\u00e9","family":"Correia","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer\u2019s Disease: Causes and Treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_2","first-page":"1","article-title":"Background paper 6.11: Alzheimer disease and other dementias","volume":"6","author":"Duthey","year":"2013","journal-title":"Public Health Approach Innov."},{"key":"ref_3","unstructured":"(2021, August 13). Depression Alzheimer\u2019s Association. Available online: https:\/\/www.alz.org\/help-support\/caregiving\/stages-behaviors\/depression."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41398-020-0839-1","article-title":"Depression\u2014An underrecognized target for prevention of dementia in Alzheimer\u2019s disease","volume":"10","author":"Dafsari","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_5","first-page":"141","article-title":"Depression in Alzheimer\u2019s Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management","volume":"12","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"ref_8","unstructured":"(2021, July 27). Dementia. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref_9","unstructured":"Kumar, A., Sidhu, J., Goyal, A., and Tsao, J.W. (2021). Alzheimer Disease, StatPearls Publishing."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-94-007-5416-4_14","article-title":"Alzheimer\u2019s Disease","volume":"65","author":"Radanovic","year":"2012","journal-title":"Subcell. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_12","first-page":"1","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4103\/1673-5374.193234","article-title":"Neurofibrillary tangles in Alzheimer\u2019s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics","volume":"11","author":"Metaxas","year":"2016","journal-title":"Neural Regen. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s Disease: Targeting the Cholinergic System","volume":"14","author":"Guimaraes","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/cam.3.1.7402","article-title":"Oxidative stress in Alzheimer disease","volume":"3","author":"Gella","year":"2009","journal-title":"Cell Adh. Migr."},{"key":"ref_18","unstructured":"(2021, August 16). BioRender Templates. Available online: https:\/\/app.biorender.com\/biorender-templates."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-019-0460-3","article-title":"Prognosis and improved outcomes in major depression: A review","volume":"9","author":"Kraus","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239821281879926","DOI":"10.1177\/2398212818799269","article-title":"The neuroscience of depressive disorders: A brief review of the past and some considerations about the future","volume":"2","author":"Kaltenboeck","year":"2018","journal-title":"Brain Neurosci. Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.31887\/DCNS.2008.10.3\/shkennedy","article-title":"Core symptoms of major depressive disorder: Relevance to diagnosis and treatment","volume":"10","author":"Kennedy","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neubiorev.2015.01.018","article-title":"Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response","volume":"51","author":"Andrews","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-017-0306-y","article-title":"The role of 5-HT receptors in depression","volume":"10","author":"Yohn","year":"2017","journal-title":"Mol. Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.npp.1301560","article-title":"Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder","volume":"33","author":"Willeit","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"PMC-S11375","DOI":"10.4137\/PMC.S11375","article-title":"Revisiting the Monoamine Hypothesis of Depression: A New Perspective","volume":"6","author":"Goldberg","year":"2014","journal-title":"Perspect. Medicin. Chem."},{"key":"ref_27","unstructured":"(2021, August 13). Alzheimer Disease Treatment & Management: Approach Considerations, Treatment of Mild to Moderate Disease, Treatment of Moderate to Severe Disease. Available online: https:\/\/emedicine.medscape.com\/article\/1134817-treatment#d12."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and Risk for Alzheimer Disease: Systematic Review, Meta-analysis, and Metaregression Analysis","volume":"63","author":"Ownby","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14656566.2018.1471136","article-title":"Pharmacotherapy for the treatment of depression in patients with alzheimer\u2019s disease: A treatment-resistant depressive disorder","volume":"19","author":"Lozupone","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamapsychiatry.2016.3162","article-title":"Prevalence of Depression in Patients with Mild Cognitive Impairment","volume":"74","author":"Ismail","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3233\/JAD-161135","article-title":"Severity of Depression Impacts Imminent Conversion from Mild Cognitive Impairment to Alzheimer\u2019s Disease","volume":"59","author":"Defrancesco","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archpsyc.63.2.161","article-title":"Increased Hippocampal Plaques and Tangles in Patients With Alzheimer Disease with a Lifetime History of Major Depression","volume":"63","author":"Rapp","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1176\/jnp.9.4.556","article-title":"Major and minor depression in Alzheimer\u2019s disease: Prevalence and impact","volume":"9","author":"Lyketsos","year":"1997","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/gps.4339","article-title":"Amyloid-associated depression and ApoE4 allele: Longitudinal follow-up for the development of Alzheimer\u2019s disease","volume":"31","author":"Qiu","year":"2016","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40120-019-00148-5","article-title":"Diagnosing and Treating Depression in Patients with Alzheimer\u2019s Disease","volume":"8","author":"Burke","year":"2019","journal-title":"Neurol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.b.10068","article-title":"Depression in Alzheimer\u2019s disease: The effect of serotonin receptor gene variation","volume":"119B","author":"Holmes","year":"2003","journal-title":"Am. J. Med. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejphar.2009.10.021","article-title":"Major depression, cognitive dysfunction and Alzheimer\u2019s disease: Is there a link?","volume":"626","author":"Sierksma","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1176\/appi.ajp.160.8.1516","article-title":"Untreated Depression and Hippocampal Volume Loss","volume":"160","author":"Sheline","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1523\/JNEUROSCI.2797-06.2006","article-title":"Glucocorticoids Increase Amyloid-beta and Tau Pathology in a Mouse Model of Alzheimer\u2019s Disease","volume":"26","author":"Green","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2174\/157015911798376262","article-title":"Neurotrophins Role in Depression Neurobiology: A Review of Basic and Clinical Evidence","volume":"9","author":"Neto","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.tins.2004.08.001","article-title":"BDNF and 5-HT: A dynamic duo in age-related neuronal plasticity and neurodegenerative disorders","volume":"27","author":"Mattson","year":"2004","journal-title":"Trends Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/1673-5374.264445","article-title":"Selective serotonin reuptake inhibitors and Alzheimer\u2019s disease","volume":"15","author":"Mdawar","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.yfrne.2015.12.001","article-title":"Depression as a risk factor for Alzheimer\u2019s disease: Genes, steroids, cytokines and neurogenesis\u2014What do we need to know?","volume":"41","author":"Herbert","year":"2016","journal-title":"Front. Neuroendocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/ng.3916","article-title":"Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease","volume":"49","author":"Sims","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/gps.4489","article-title":"Amyloid burden and incident depressive symptoms in cognitively normal older adults","volume":"32","author":"Harrington","year":"2017","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e198964","DOI":"10.1001\/jamanetworkopen.2019.8964","article-title":"Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults","volume":"2","author":"Gatchel","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cassano, T., Calcagnini, S., Carbone, A., Bukke, V.N., Orkisz, S., Villani, R., Romano, A., Avolio, C., and Gaetani, S. (2019). Pharmacological Treatment of Depression in Alzheimer\u2019s Disease: A Challenging Task. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01067"},{"key":"ref_49","unstructured":"(2021, August 16). BioRender. Available online: https:\/\/biorender.com\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2174\/138161206777698909","article-title":"Serotonin and Human Cognitive Performance","volume":"12","author":"Schmitt","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2009.10.022","article-title":"Depression and Alzheimer\u2019s disease: Neurobiological links and common pharmacological targets","volume":"626","author":"Caraci","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40263-018-0590-9","article-title":"Impact of Antidepressant Use on the Trajectory of Alzheimer\u2019s Disease: Evidence, Mechanisms, and Therapeutic Implications","volume":"33","author":"Khoury","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jad.2008.11.020","article-title":"Antidepressants and dementia","volume":"117","author":"Kessing","year":"2009","journal-title":"J. Affect. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","article-title":"Treating Depression in Alzheimer Disease","volume":"60","author":"Lyketsos","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0b013e31802e0002","article-title":"Does Fluoxetine Have Any Effect on the Cognition of Patients with Mild Cognitive Impairment?","volume":"27","author":"Mowla","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer\u2019s Dementia in Individuals With Previous Depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","article-title":"Serotonin signaling is associated with lower amyloid-\u03b2 levels and plaques in transgenic mice and humans","volume":"108","author":"Cirrito","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","first-page":"a006346","article-title":"Inflammation in Alzheimer Disease\u2014A Brief Review of the Basic Science and Clinical Literature","volume":"2","author":"Rogers","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_59","first-page":"236re4","article-title":"An Antidepressant Decreases CSF A Production in Healthy Individuals and in Transgenic AD Mice","volume":"6","author":"Sheline","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.08.037","article-title":"Fluoxetine administration during adolescence attenuates cognitive and synaptic deficits in adult 3\u00d7TgAD mice","volume":"126","author":"Sun","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2174\/1567205011666140812114715","article-title":"Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble \u03b2-Amyloid in APP\/PS1 Mice","volume":"11","author":"Wang","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/glia.22926","article-title":"Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP\/PS1 mouse model","volume":"64","author":"Qiao","year":"2016","journal-title":"Glia"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Caraci, F., Tascedda, F., Merlo, S., Benatti, C., Spampinato, S.F., Munaf\u00f2, A., Leggio, G.M., Nicoletti, F., Brunello, N., and Drago, F. (2016). Fluoxetine Prevents A\u03b21-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-\u03b21. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00389"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.18632\/oncotarget.7798","article-title":"Escitalopram attenuates \u03b2-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt\/GSK-3\u03b2 pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.expneurol.2007.01.037","article-title":"Prophylactic Treatment with Paroxetine Ameliorates Behavioral Deficits and Retards the Development of Amyloid and Tau Pathologies in 3xTgAD Mice","volume":"205","author":"Nelson","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3233\/JAD-171001","article-title":"Effect of Fluvoxamine on Amyloid-\u03b2 Peptide Generation and Memory","volume":"62","author":"Kim","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/acschemneuro.8b00160","article-title":"Interactions of Selective Serotonin Reuptake Inhibitors with \u03b2-Amyloid","volume":"10","author":"Tin","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3233\/JAD-181145","article-title":"Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers","volume":"67","author":"La","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_69","first-page":"1","article-title":"A tricyclic antidepressant, amoxapine, reduces amyloid-\u03b2 generation through multiple serotonin receptor 6-mediated targets","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ntt.2017.05.002","article-title":"Pre-treatment with amitriptyline causes epigenetic up-regulation of neuroprotection-associated genes and has anti-apoptotic effects in mouse neuronal cells","volume":"62","author":"Tran","year":"2017","journal-title":"Neurotoxicol. Teratol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1142\/S021963521650014X","article-title":"Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer\u2019s disease associated mice","volume":"15","author":"Wang","year":"2016","journal-title":"J. Integr. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/jpet.109.162164","article-title":"Imipramine, in Part through Tumor Necrosis Factor \u03b1 Inhibition, Prevents Cognitive Decline and \u03b2-Amyloid Accumulation in a Mouse Model of Alzheimer\u2019s Disease","volume":"332","author":"Chavant","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_73","first-page":"1408412","article-title":"Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice","volume":"25","author":"Li","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejphar.2015.07.015","article-title":"Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A\u03b2(1\u201342)-induced toxicity","volume":"764","author":"Caraci","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: At the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"ref_77","unstructured":"Chu, A., and Wadhwa, R. (2021). Selective Serotonin Reuptake Inhibitors, StatPearls Publishing."},{"key":"ref_78","unstructured":"Moraczewski, J., and Aedma, K.K. (2020). Tricyclic Antidepressants, StatPearls Publishing."},{"key":"ref_79","unstructured":"Laban, T.S., and Saadabadi, A. (2021). Monoamine Oxidase Inhibitors (MAOI), StatPearls Publishing."},{"key":"ref_80","unstructured":"Shin, J.J., and Saadabadi, A. (2021). Trazodone, StatPearls Publishing."},{"key":"ref_81","unstructured":"Rosenbaum, S.B., Gupta, V., and Palacios, J.L. (2021). Ketamine, StatPearls Publishing."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Alam, A., Voronovich, Z., and Carley, J.A. (2013). A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions. Prim. Care Companion CNS Disord., 15.","DOI":"10.4088\/PCC.13r01525"},{"key":"ref_83","unstructured":"Jilani, T.N., Gibbons, J.R., Faizy, R.M., and Saadabadi, A. (2021). Mirtazapine, StatPearls Publishing."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Watanabe, N., Omori, I.M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R., and Furukawa, T.A. (2011). Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst. Rev., 12.","DOI":"10.1002\/14651858.CD006528.pub2"},{"key":"ref_85","first-page":"311","article-title":"Mirtazapine-Induced Nightmares","volume":"8","author":"Matthews","year":"2006","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00045391-200007030-00008","article-title":"Recognition and Management of Depression in Primary Care","volume":"7","author":"Barkin","year":"2000","journal-title":"Am. J. Ther."},{"key":"ref_87","unstructured":"Kessler, D., Burns, A., Tallon, D., Lewis, G., MacNeill, S., Round, J., Hollingworth, W., Chew-Graham, C., Anderson, I., and Campbell, J. (2018). Introduction, NIHR Journals Library."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2009.01.015","article-title":"Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation","volume":"19","author":"Blier","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","article-title":"Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study","volume":"167","author":"Blier","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.jcp.0000085408.08426.05","article-title":"Mirtazapine orally disintegrating tablet versus sertraline: A prospective onset of action study","volume":"23","author":"Behnke","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_91","unstructured":"(2021, August 06). Remeron, Remeron SolTab (Mirtazapine) Dosing, Indications, Interactions, Adverse Effects, and More. Available online: https:\/\/reference.medscape.com\/drug\/remeron-soltab-mirtazapine-342966#4."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/YIC.0b013e328330adb2","article-title":"Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression","volume":"25","author":"Thase","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4068\/cmj.2018.54.2.101","article-title":"Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review","volume":"54","author":"Wang","year":"2018","journal-title":"Chonnam Med. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0006-3223(00)00882-9","article-title":"Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study","volume":"48","author":"Winokur","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00004850-200111000-00008","article-title":"The effect of mirtazapine in panic disorder: An open label pilot study with a single-blind placebo run-in period","volume":"16","author":"Boshuisen","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_97","unstructured":"(2021, July 21). Anxiety Disorders Treatment & Management: Approach Considerations, Pharmacotherapy for Anxiety and Panic Disorders, Psychotherapy for Anxiety and Panic Disorders. Available online: https:\/\/emedicine.medscape.com\/article\/286227-treatment#d8."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hup.426","article-title":"Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: A pilot study","volume":"17","author":"Bahk","year":"2002","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1345\/aph.1M009","article-title":"An Open-Label Study of Mirtazapine as Treatment for Combat-Related PTSD","volume":"43","author":"Alderman","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for Obsessive-Compulsive Disorder: An Open Trial Followed by Double-Blind Discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","article-title":"Response Acceleration With Mirtazapine Augmentation of Citalopram in Obsessive-Compulsive Disorder Patients Without Comorbid Depression","volume":"65","author":"Pallanti","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1742-1241.2010.02624.x","article-title":"Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: An 8-week open-label randomised paroxetine-controlled trial","volume":"65","author":"Kim","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1177\/0269881120965939","article-title":"Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial","volume":"34","author":"MacNeill","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/YIC.0b013e32833a4d71","article-title":"Mirtazapine in generalized social anxiety disorder: A randomized, double-blind, placebo-controlled study","volume":"25","author":"Schutters","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_105","first-page":"301","article-title":"Migraine headache prophylaxis and treatment with low-dose mirtazapine","volume":"18","author":"Margolese","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_106","unstructured":"(2021, July 21). Mirtazapine: A Medicine to Treat Depression, Obsessive Compulsive Disorder and Anxiety Disorders\u2014NHS. Available online: https:\/\/www.nhs.uk\/medicines\/mirtazapine\/."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/bs.podrm.2018.01.002","article-title":"Mirtazapine","volume":"43","author":"Bakheit","year":"2018","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s002100000294","article-title":"Interaction of the antidepressant mirtazapine with \u03b12-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo","volume":"362","author":"Bengtsson","year":"2000","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00213-013-3146-1","article-title":"Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: A positron emission tomography study in healthy volunteers","volume":"230","author":"Sato","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/sj.npp.1300923","article-title":"Changes of Sleep Architecture, Spectral Composition of Sleep EEG, the Nocturnal Secretion of Cortisol, ACTH, GH, Prolactin, Melatonin, Ghrelin, and Leptin, and the DEX-CRH Test in Depressed Patients during Treatment with Mirtazapine","volume":"31","author":"Schmid","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-200038060-00001","article-title":"Clinical Pharmacokinetics of Mirtazapine","volume":"38","author":"Timmer","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1570159X14666151208114232","article-title":"Drug Therapy for Behavioral and Psychological Symptoms of Dementia","volume":"14","author":"Wang","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1345\/aph.10371","article-title":"Mirtazapine for Treatment of Depression and Comorbidities in Alzheimer Disease","volume":"35","author":"Raji","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2147\/NDT.S3201","article-title":"The efficacy of mirtazapine in agitated patients with Alzheimer\u2019s disease: A 12-week open-label pilot study","volume":"4","author":"Cakir","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","article-title":"Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial","volume":"378","author":"Banerjee","year":"2011","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jagp.2019.03.021","article-title":"Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial","volume":"27","author":"Zuidersma","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/psyg.12191","article-title":"Mirtazapine does not improve sleep disorders in Alzheimer\u2019s disease: Results from a double-blind, placebo-controlled pilot study","volume":"17","author":"Scoralick","year":"2017","journal-title":"Psychogeriatrics"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"He, Y., Li, H., Huang, J., Huang, S., Bai, Y., Li, Y., and Huang, W. (2021). Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis. J. Psychopharmacol.","DOI":"10.1177\/02698811211030181"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnmol.2021.661728","article-title":"Amyloid-\u03b2 Impairs Dendritic Trafficking of Golgi-Like Organelles in the Early Phase Preceding Neurite Atrophy: Rescue by Mirtazapine","volume":"14","author":"Fabbretti","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"117957352090739","DOI":"10.1177\/1179573520907397","article-title":"Current and Future Treatments in Alzheimer Disease: An Update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_121","unstructured":"(2021, September 01). Drug Interactions Checker\u2014Medscape Drug Reference Database. Available online: https:\/\/reference.medscape.com\/drug-interactionchecker."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Miziak, B., B\u0142aszczyk, B., and Czuczwar, S.J. (2021). Some Candidate Drugs for Pharmacotherapy of Alzheimer\u2019s Disease. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050458"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/9\/930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:45Z","timestamp":1760166045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/9\/930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":123,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ph14090930"],"URL":"https:\/\/doi.org\/10.3390\/ph14090930","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}